IP Library Granted Patent US 7,714,063
Granted Patent B2
US 7,714,063 · App. 12/264,948 · Granted May 11, 2010

Solid support for Fmoc-solid phase synthesis of peptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,714,063
App. No.
12/264,948
Granted
May 11, 2010
Kind
B2
Abstract

The present invention provides compositions and processes for the solid phase synthesis of polypeptides. In particular, the present invention provides solid supports and processes for preparing solid supports for the synthesis of polypeptides.

Claims (64)

1. A compound comprising Formula (I):

wherein:

R 2 and R 4 are hydrocarbyl;

R 3 is selected from the group consisting of hydrogen, a protecting group, an amino acid residue, and a peptide;

R 5 is a solid support comprising at least one polymer; and

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

2. The compound of claim 1 , wherein R 3 is selected from the group consisting of Fmoc and a peptide; and R 5 is polystyrene cross-linked with divinylbenzene.

3. The compound of claim 2 , wherein the peptide has a C-terminus secondary amine.

4. The compound of claim 1 , comprising:

wherein:

R 3 is selected from the group consisting of hydrogen, a protecting group, an amino acid residue, and a peptide;

R 5 is a solid support comprising at least one polymer;

m is an integer from 1 to 8; and

n is an integer from 1 to 8.

5. The compound of claim 4 , wherein R 3 is selected from the group consisting of Fmoc and a peptide; and R 5 is polystyrene cross-linked with divinylbenzene.

6. The compound of claim 5 , wherein the peptide has a C-terminus secondary amine.

7. The compound of claim 1 , comprising:

wherein:

R 3 is selected from the group consisting of hydrogen, a protecting group, an amino acid residue, and a peptide; and

R 5 is a solid support comprising at least one polymer.

8. The compound of claim 7 , wherein R 3 is selected from the group consisting of Fmoc and a peptide; and R 5 is polystyrene cross-linked with divinylbenzene.

9. The compound of claim 8 , wherein the peptide has a C-terminus secondary amine.

10. The compound of claim 8 , wherein the peptide is selected from the group consisting of Leuprolide, Deslorelin, Buserelin, Alarelin, Fertirelin, and Histrelin.

11. A process for making a solid support, the process comprising:

(a) combining a compound comprising formula (1) with a compound comprising formula (2) in the presence of a base to produce a compound comprising formula (3), wherein the compound comprising formula (1) has the following structure:

wherein:

R 4 is hydrocarbyl; and

R 5 is a solid support comprising at least one polymer;

the compound comprising formula (2) has the following structure:

wherein:

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl; and

the compound comprising formula (3) has the following structure:

wherein:

R 4 is hydrocarbyl;

R 5 is a solid support comprising at least one polymer; and

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

(b) contacting the compound comprising formula (3) with a reducing agent and a compound comprising R 2 NH 2 , wherein R 2 is hydrocarbyl, to produce a solid support comprising formula (I);

wherein:

R 2 and R 4 are hydrocarbyl;

R 5 is a solid support comprising at least one polymer; and

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl.

12. The process of claim 11 , wherein the base is selected from the group consisting of sodium methoxide, potassium carbonate, lithium carbonate, sodium carbonate, magnesium carbonate, calcium carbonate, and strontium carbonate; and the amount of compound 1 to the amount of compound 2 to the amount of base is a molar ratio ranging from about 1:1:1 to about 1:5:5.

13. The process of claim 11 , wherein the reducing agent is selected from the group consisting of sodium borohydride, sodium cyanoborohydride, diisobutylaluminium hydride, lithium aluminium hydride, and titanium isopropoxide sodium borohydride; and the amount of compound 3 to the amount of R 2 NH 2 to the amount of reducing agent is a molar ratio ranging from about 1:1:1 to about 1:10:20.

14. The process of claim 11 , wherein the base is potassium carbonate; the reducing agent is sodium borohydride; the amount of compound 1 to the amount of compound 2 to the amount of potassium carbonate is a molar ratio ranging from about 1:1:1 to about 1:5:5; and the amount of compound 3 to the amount of R 2 NH 2 to the amount of sodium borohydride is a molar ratio ranging from about 1:1:1 to about 1:10:20.

15. The process of claim 11 , wherein:

the compound comprising formula (1) has the following structure:

the compound comprising formula (2) has the following structure:

the compound comprising formula (3) has the following structure:

and the compound comprising formula (I) has the following structure:

wherein R 5 is solid support comprising at least one polymer.

16. The process of claim 15 , wherein R 5 is polystyrene cross-linked with divinylbenzene; the base is potassium carbonate; the R 2 NH 2 is ethylamine; the reducing agent is sodium borohydride; the amount of compound 1 to the amount of compound 2 to the amount about of potassium carbonate is a molar ratio ranging from about 1:1:1 to about 1:5:5; and the amount of compound 3 to the amount of ethylamine to the amount of sodium borohydride is a molar ratio ranging from about 1:1:1 to about 1:10:20.

17. A method for synthesizing a polypeptide, the method comprising:

(a) activating the carboxyl group of an amino acid that has its amine protected by a Fmoc group, and its side chain protected by an acid labile group;

(b) coupling the activated amino acid to the amino group of a solid support comprising Formula (I):

wherein:

R 2 and R 4 are hydrocarbyl;

R 5 is a solid support comprising at least one polymer; and

R 6 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

(c) treatment of the solid support with a base to deprotect the amine group of the amino acid protected with Fmoc; and

(d) repeating steps (a) to (c) until the target polypeptide is synthesized.

18. The method of claim 17 , wherein the polypeptide is selected from the group consisting of Leuprolide, Deslorelin, Buserelin, Alarelin, Fertirelin, and Histrelin.

19. The method of claim 17 , further comprising cleaving the target polypeptide from the solid support by contacting the solid support of step (d) with a weak acid and a scavenger selected from the group consisting of phenol, water, 1,2-ethanedithiol, and triisopropylsilane.

20. The method of claim 17 , wherein the solid support has the following structure:

wherein R 5 is polystyrene cross-linked with divinylbenzene.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2008
From: SRIVASTAVA, KRIPA S.; DAVIS, MATTHEW R.
To: MALLINCKRODT INC.
Reel/Frame 021786/0880 →